UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,301	06/11/2007	Salehuzzaman Shah	080426-000000US	2658
TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER			EXAMINER	
			MCELWAIN, ELIZABETH F	
EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			ART UNIT	PAPER NUMBER
			1638	
			MAIL DATE	DELIVERY MODE
			03/04/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/583,301	SHAH ET AL.
Office Action Summary	Examiner	Art Unit
	Elizabeth F. McElwain	1638
The MAILING DATE of this communication ap	opears on the cover sheet with th	ne correspondence address
Period for Reply	LV IO OET TO EVEIDE « MONI	FLVO) OD TUUDTV (OO) DAVO
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICAT .136(a). In no event, however, may a reply b d will apply and will expire SIX (6) MONTHS to te, cause the application to become ABANDO	ION. be timely filed from the mailing date of this communication. DNED (35 U.S.C. § 133).
Status		
1) ■ Responsive to communication(s) filed on 16. 2a) ■ This action is FINAL . 2b) ■ Th 3) ■ Since this application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters,	
Disposition of Claims		
4) Claim(s) 1-17,26 and 32 is/are pending in the 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-17, 26 and 32 are subject to restrict.	awn from consideration.	nt.
Application Papers		
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the corre 11) The oath or declaration is objected to by the E	ccepted or b) objected to by the drawing(s) be held in abeyance.	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the pri application from the International Burea * See the attached detailed Office action for a list	nts have been received. nts have been received in Applic ority documents have been rece au (PCT Rule 17.2(a)).	cation No eived in this National Stage
Attachment(s)	_	
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	4) Interview Summ Paper No(s)/Ma 5) Notice of Inform 6) Other:	

DETAILED ACTION

The amendment filed June 16, 2006 has been entered.

Claims 1-17, 26 and 32 are pending.

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-10, drawn to a recombinant polypeptide comprising a delta-9 desaturase from a prokaryote.

Group II, claim(s) 11-17, 26 and 32, drawn to a nucleic acid encoding a delta-9 desaturase, and a vector, host cell and plant comprising said nucleic acid and a method of extracting oil from said plant.

1. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The nucleic acid of Group II does not share a special technical feature with the polypeptide of Group I. According to the PCT Administrative Instructions, for molecules to be of similar nature, they need to share a common core structure and a common property or activity. Nor does the relationship of the polypeptides of Group I and the polynucleotides of Group II conform with Example 17 of the PCT Administrative Instructions. The instant claims are not directed to a single molecule, but encompass a family of molecules which are defined by a minimal structure. For these reasons, there is no shared technical feature between the nucleic acids of Group II and the polypeptides of Group I.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and the requirement for different searches, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth F. McElwain whose telephone number is (571) 272-0802. The examiner can normally be reached on increased flex time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on (571) 272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/583,301 Page 4

Art Unit: 1638

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

EFM

/Elizabeth F. McElwain/ Primary Examiner, Art Unit 1638